Cryocell International Stock Analysis
| CCEL Stock | USD 8.67 0.42 4.62% |
CryoCell International is undervalued with Real Value of 9.04 and Target Price of 10.0. The main objective of CryoCell International stock analysis is to determine its intrinsic value, which is an estimate of what CryoCell International is worth, separate from its market price. There are two main types of CryoCell International's stock analysis: fundamental analysis and technical analysis.
The CryoCell International stock is traded in the USA on NYSE MKT Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
CryoCell |
CryoCell Stock Analysis Notes
About 48.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.07. CryoCell International last dividend was issued on the 15th of November 2024. Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida. Cryo-Cell Intl operates under Medical Care Facilities classification in the United States and is traded on AMEX Exchange. It employs 83 people. For more info on CryoCell International please contact Mark Portnoy at 813 749 2100 or go to https://www.cryo-cell.com.CryoCell International Quarterly Total Revenue |
|
CryoCell International Investment Alerts
| CryoCell International appears to be risky and price may revert if volatility continues | |
| CryoCell International currently holds 10.9 M in liabilities with Debt to Equity (D/E) ratio of 0.26, which may suggest the company is not taking enough advantage from borrowing. CryoCell International has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about CryoCell International's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 31.34 M. Net Loss for the year was (9.52 M) with profit before overhead, payroll, taxes, and interest of 21.54 M. | |
| CryoCell International has a poor financial position based on the latest SEC disclosures | |
| About 48.0% of CryoCell International shares are held by company insiders | |
| On 29th of November 2024 CryoCell International paid $ 0.25 per share dividend to its current shareholders | |
| Latest headline from MacroaxisInsider: Disposition of 10000 shares by Oleg Mikulinsky of CryoCell International at 4.34 subject to Rule 16b-3 |
CryoCell International Upcoming and Recent Events
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 30th of November 2023 Next Fiscal Quarter End | View |
CryoCell Largest EPS Surprises
Earnings surprises can significantly impact CryoCell International's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-07-15 | 2024-05-31 | 0.04 | 0.08 | 0.04 | 100 | ||
2024-04-15 | 2024-02-29 | -0.02 | 0.07 | 0.09 | 450 | ||
2024-10-15 | 2024-08-31 | 0.02 | 0.13 | 0.11 | 550 |
CryoCell International Environmental, Social, and Governance (ESG) Scores
CryoCell International's ESG score is a quantitative measure that evaluates CryoCell International's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of CryoCell International's operations that may have significant financial implications and affect CryoCell International's stock price as well as guide investors towards more socially responsible investments.
CryoCell Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-06-30 | 57.0 | Jpmorgan Chase & Co | 2024-06-30 | 11.0 | Rowland & Co Investment Counsel | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Hamilton Lane Advisors Llc | 2024-09-30 | 409.7 K | Sfi Advisors, Llc | 2024-06-30 | 165.3 K | Vanguard Group Inc | 2024-09-30 | 116.8 K | Massmutual Trust Co Fsb/adv | 2024-09-30 | 111 K | Geode Capital Management, Llc | 2024-09-30 | 39.9 K | Northern Trust Corp | 2024-09-30 | 21.8 K | Hpm Partners Llc | 2024-06-30 | 19.6 K |
CryoCell Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 73.28 M.CryoCell Profitablity
The company has Profit Margin (PM) of (0.28) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.17 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.17.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.14) | |
| Return On Capital Employed | (0.27) | (0.26) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | 0.99 | 1.04 |
Management Efficiency
Return On Equity is expected to rise to 1.04 this year, although the value of Return On Tangible Assets are projected to rise to (0.14). At this time, CryoCell International's Asset Turnover is quite stable compared to the past year. CryoCell International's management efficiency ratios could be used to measure how well CryoCell International manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.52) | (1.44) | |
| Tangible Book Value Per Share | (1.92) | (1.83) | |
| Enterprise Value Over EBITDA | (6.08) | (5.78) | |
| Price Book Value Ratio | (4.65) | (4.42) | |
| Enterprise Value Multiple | (6.08) | (5.78) | |
| Price Fair Value | (4.65) | (4.42) | |
| Enterprise Value | 63.4 M | 60.2 M |
CryoCell International benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Dividend Yield 0.1153 | Operating Margin 0.1739 | Profit Margin (0.28) | Forward Dividend Yield 0.1153 | Beta 0.512 |
Technical Drivers
As of the 1st of December, CryoCell International shows the Mean Deviation of 3.29, downside deviation of 2.84, and Risk Adjusted Performance of 0.1013. CryoCell International technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm CryoCell International jensen alpha, potential upside, as well as the relationship between the Potential Upside and skewness to decide if CryoCell International is priced correctly, providing market reflects its regular price of 8.67 per share. Given that CryoCell International has jensen alpha of 0.5665, we suggest you to validate CryoCell International's prevailing market performance to make sure the company can sustain itself at a future point.CryoCell International Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. CryoCell International middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for CryoCell International. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
CryoCell International Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CryoCell International insiders, such as employees or executives, is commonly permitted as long as it does not rely on CryoCell International's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CryoCell International insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CryoCell International Outstanding Bonds
CryoCell International issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CryoCell International uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CryoCell bonds can be classified according to their maturity, which is the date when CryoCell International has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
CryoCell International Predictive Daily Indicators
CryoCell International intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CryoCell International stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
CryoCell International Corporate Filings
F4 | 14th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 12th of November 2024 Other Reports | ViewVerify | |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 17th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 15th of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 7th of October 2024 Other Reports | ViewVerify | |
8K | 17th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
CryoCell International Forecast Models
CryoCell International's time-series forecasting models are one of many CryoCell International's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary CryoCell International's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About CryoCell Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how CryoCell International prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CryoCell shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as CryoCell International. By using and applying CryoCell Stock analysis, traders can create a robust methodology for identifying CryoCell entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.38) | (0.36) | |
| Operating Profit Margin | (0.35) | (0.37) | |
| Net Loss | (0.27) | (0.29) | |
| Gross Profit Margin | 0.66 | 0.56 |
Current CryoCell Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CryoCell analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CryoCell analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 10.0 | Buy | 1 | Odds |
Most CryoCell analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand CryoCell stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of CryoCell International, talking to its executives and customers, or listening to CryoCell conference calls.
CryoCell Stock Analysis Indicators
CryoCell International stock analysis indicators help investors evaluate how CryoCell International stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading CryoCell International shares will generate the highest return on investment. By understating and applying CryoCell International stock analysis, traders can identify CryoCell International position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 1.7 M | |
| Long Term Debt | 8.4 M | |
| Common Stock Shares Outstanding | 8.3 M | |
| Total Stockholder Equity | -11 M | |
| Tax Provision | -3.8 M | |
| Quarterly Earnings Growth Y O Y | 0.625 | |
| Property Plant And Equipment Net | 22 M | |
| Cash And Short Term Investments | 980.2 K | |
| Cash | 406.1 K | |
| Accounts Payable | 3.2 M | |
| Net Debt | 10.5 M | |
| 50 Day M A | 7.167 | |
| Total Current Liabilities | 20.9 M | |
| Other Operating Expenses | 43.6 M | |
| Non Current Assets Total | 51.8 M | |
| Non Currrent Assets Other | 6.3 M | |
| Stock Based Compensation | 816.6 K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.625 | Earnings Share (1.07) | Revenue Per Share 3.89 | Quarterly Revenue Growth 0.025 | Return On Assets (0) |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.